Main Article Content

Abstract

The goal of this work was to use an unique in vivo screening strategy to examine the antipsoriatic effect of ethanolic extract of Morinda reticulata (EEMR). For psoriasis induction, 0.1 ml of prepared complete Freund's adjuvant (CFA) & formaldehyde mixture (1:10) was topically administered to the dorsum surface of Swiss albino mice's skin for 7 days. The phenotypic (redness, erythema, and scales) & histological aspects of psoriasis severity index (PSI) were assessed (epidermal thickness). After inducing psoriasis, the therapeutic impact of 0.05 percent and 0.1 percent (w/w) EEMR ointments was examined. The antipsoriatic activity of EEMR ointments was assessed using the PSI and histological investigation after they were applied once daily for three weeks. In animals treated with 0.05 percent and 0.1 percent (w/w) ointments of EEMR, we observed phenotypic and histological features & found a progressive reduction (P 0.05) in the severity of psoriatic lesions (redness, erythema, & scales) from day 7 to day 21 as well as decreased epidermal thickness. The findings revealed that 0.1 percent (w/w) EEMR ointments have dose-dependent therapeutic effects in CFA & formaldehyde-induced psoriasis. The current study discovered that M.reticulata  has substantial antipsoriatic activity and can be used to treat psoriasis.

Keywords

Flavonoids Formaldehyde Inflammation Psoriasis Morinda reticulate

Article Details

How to Cite
A.Kavidha, & Sam Ancil Andrew. (2022). Antipsoriatic activity of ethanolic extract of morinda reticulata in a novel in vivo screening model. International Journal of Research in Pharmacology & Pharmacotherapeutics, 11(1), 27-35. Retrieved from https://ijrpp.com/ijrpp/article/view/420

References

  1. 1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-71. doi: 10.1016/S0140-6736(07)61128-3, PMID 17658397.
  2. 2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664-75. doi: 10.1172/JCI22147, PMID 15199399.
  3. 3. Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends Genet. 2010;26(9):415-23. doi: 10.1016/j.tig.2010.06.006, PMID 20692714.
  4. 4. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated? understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32-8. PMID 20725536.
  5. 5. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal formulae in the management of psoriasis: systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs. Phytother Res. 2014;28(4):480-97. doi: 10.1002/ptr.5028, PMID 23817996.
  6. 6. Available from: http://keralaplants.in/keralaplantsdetails.aspx?id=Morinda_reticulata.
  7. 7. Esau K. Plant anatomy. Soil Science. 1953;75(5):767. doi: 10.1097/00010694-195305000-00014.
  8. 8. Khandelwal KR. Practical pharmacognosy techniques and experiments. Pune: Nirali Prakashan; 2000.
  9. 9. Sadasivam S, Manickam A. Biochemical methods. New Delhi: new age international (P) limited; 1996.
  10. 10. Ordonez AA, Gomez JD, Vattuone MA, Lsla MI. Antioxidant activities of Sechium edule (Jacq.) Swart extracts. Food Chem. 2006;97(3):452-8. doi: 10.1016/j.foodchem.2005.05.024.
  11. 11. Vogel GH. Drug discovery and evaluation: pharmacological assays. New York: Springer; 2002.
  12. 12. Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70(6):849-60. PMID 11739546.
  13. 13. Xu B, Aoyama K, Takeuchi M, Matsushita T, Takeuchi T. Expression of cytokine mRNAs in mice cutaneously exposed to formaldehyde. Immunol Lett. 2002;84(1):49-55. doi: 10.1016/s0165-2478(02)00126-8, PMID 12161283.
  14. 14. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64;Suppl 2:ii65-8; discussion ii69. doi: 10.1136/ard.2004.031237, PMID 15708941.
  15. 15. Organization economic for cooperation and development (OECD). Guidelines for testing of chemicals. Acute Dermal Toxicity, Test No. 402. France: OECD; 2001.
  16. 16. Broderson JR. A retrospective review of lesions associated with the use of Freund’s adjuvant. Lab Anim Sci. 1989;39(5):400-5. PMID 2811278.
  17. 17. Wanstrup J, Christensen HE. Granulomatous lesions in mice produced by Freund’s adjuvant; morphogenesis and phasic development. Acta Pathol Microbiol Scand. 1965;63:340-54. doi: 10.1111/apm.1965.63.3.340, PMID 14322318.
  18. 18. Saito A, Tanaka H, Usuda H, Shibata T, Higashi S, Yamashita H, Inagaki N, Nagai H. Characterization of skin inflammation induced by repeated exposure of toluene, xylene, and formaldehyde in mice. Environ Toxicol. 2011;26(3):224-32. doi: 10.1002/tox.20547, PMID 19904815.
  19. 19. Amigó M, Payá M, De Rosa S, Terencio MC. Antipsoriatic effects of avarol-3′-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. Br J Pharmacol. 2007;152(3):353-65. doi: 10.1038/sj.bjp.0707394, PMID 17641670.
  20. 20. Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg. 2002;6(3);Suppl:2-7 [Suppl:2-7]. doi: 10.1177/12034754020060S302, PMID 11976985.
  21. 21. Cameron AL, Kirby B, Fei W, Griffiths CE. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res. 2002;294(8):363-9. doi: 10.1007/s00403-002-0349-4, PMID 12420105.
  22. 22. Kaur A, Kumar S. Plants and plant products with potential antipsoriatic activity - a review. Pharm Biol. 2012;50(12):1573-91. doi: 10.3109/13880209.2012.690430, PMID 22971237.
  23. 23. Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol. 2008;128(11):2606-14. doi: 10.1038/jid.2008.122, PMID 18463678.
  24. 24. Middleton E Jr., Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751. PMID 11121513.
  25. 25. González R, Ballester I, López-Posadas R, Suárez MD, Zarzuelo A, Martínez-Augustin O, Sánchez de Medina F. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr. 2011;51(4):331-62. doi: 10.1080/10408390903584094, PMID 21432698.